首页    期刊浏览 2024年11月23日 星期六
登录注册

文章基本信息

  • 标题:A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder
  • 本地全文:下载
  • 作者:Caroul Chawar ; Alannah Hillmer ; Stephanie Sanger
  • 期刊名称:Addiction Science & Clinical Practice
  • 电子版ISSN:1940-0640
  • 出版年度:2021
  • 卷号:16
  • DOI:10.1186/s13722-021-00278-y
  • 语种:English
  • 出版社:BioMed Central
  • 摘要:Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. Objectives This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. Methods Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. Results Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10 –7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. Limitations The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. Conclusion The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121. Supplementary Information The online version contains supplementary material available at 10.1186/s13722-021-00278-y.
  • 关键词:Opioid; Pharmacogenetic; MOUD; Methadone; GWAS; Systematic review
国家哲学社会科学文献中心版权所有